Skip to main content

Table 3 Categorisation 2: non-high FeNO and non-high blood eosinophils vs. non-high FeNO and high blood eosinophils

From: Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations

Characteristics

Non-high FeNO and non-high blood eosinophils (n = 186)

Non-high FeNO and high blood eosinophils (n = 186)

p-value

Sex

 n (% non-missing)

186 (100.0)

186 (100.0)

1.0000

 Male

77 (41.4)

77 (41.4)

 

Age

 n (% non-missing)

186 (100.0)

186 (100.0)

0.9834

 Mean (SD)

51.9 (13.1)

51.8 (13.7)

 

 Median (IQR)

55.0 (20.0)

53.5 (20.0)

 

Age group

 n (% non-missing)

186 (100.0)

186 (100.0)

0.1919

 Under 35

22 (11.8)

24 (12.9)

 

 35–65

141 (75.8)

127 (68.3)

 

 44–80

23 (12.4)

35 (18.8)

 

Smoking status

 n (% non-missing)

186 (100.0)

186 (100.0)

1.0000

 Non-smoker

67 (36.0)

67 (36.0)

 

 Ex-smoker

22 (11.8)

22 (11.8)

 

 Current smoker

67 (36.0)

67 (36.0)

 

BMI

 n (% non-missing)

184 (98.4)

184 (98.4)

0.0492

 Mean (SD)

30.1 (6.3)

29.0 (6.7)

 

FeNO

 n (% non-missing)

186 (100.0)

186 (100.0)

<0.0001

 Mean (SD)

16.5 (7.8)

28.9 (23.8)

 

 Median (IQR)

16.0 (12.0)

23.0 (22.0)

 

Blood eosinophil count

 n (% non-missing)

186 (100.0)

184 (98.9)

<0.0001

 Mean (SD)

0.2 (0.1)

0.4 (0.2)

 

 Median (IQR)

0.2 (0.1)

0.4 (0.2)

 

Active eczema diagnosisa

 n (% non-missing)

186 (100.0)

186 (100.0)

0.1876

 Yes

5 (2.7)

10 (5.4)

 

Active rhinitis diagnosisa

 n (% non-missing)

186 (100.0)

186 (100.0)

0.0720

 Yes

49 (26.3)

65 (34.9)

 

Eczema diagnosis

   

 n (% non-missing)

186 (100.0)

186 (100.0)

0.2273

 Yes

57 (30.6)

68 (36.6)

 

Rhinitis diagnosis

 n (% non-missing)

186 (100.0)

186 (100.0)

0.0272

 Yes

67 (36.0)

88 (47.3)

 

IHD diagnosis

   

 n (% non-missing)

186 (100.0)

186 (100.0)

0.4564

 Yes

7 (3.8)

10 (5.4)

 

Heart failure diagnosis

 n (% non-missing)

186 (100.0)

186 (100.0)

0.3167

 Yes

0 (0.0)

1 (0.5)

 

Hypertension diagnosis

 n (% non-missing)

186 (100.0)

186 (100.0)

0.3212

 Yes

46 (24.7)

38 (20.4)

 

Diabetes diagnosis

   

 n (% non-missing)

186 (100.0)

186 (100.0)

0.5736

 Yes

14 (7.5)

17 (9.1)

 

GERD active diagnosis

 N (% non-missing)

186 (100.0)

186 (100.0)

0.4352

 Yes

26 (14.0)

21 (11.3)

 

Predicted peak flow

   

 n (% non-missing)

98 (52.7)

101 (54.3)

0.8525

 Mean (SD)

515.7 (75.3)

517.3 (76.2)

 

ICS/LABA prescriptions per patient

 n (% non-missing)

186 (100.0)

186 (100.0)

0.0404

 Mean (SD)

3.8 (3.9)

4.4 (3.8)

 

 Median (IQR)

3.0 (6.0)

4.0 (5.0)

 

Mono ICS prescriptions per patient

 n (% non-missing)

186 (100.0)

186 (100.0)

0.0362

 Mean (SD)

1.3 (2.5)

0.7 (1.6)

 

 Median (IQR)

0.0 (1.0)

0.0 (1.0)

 

Mean daily SABA dosage (µg)

 n (% non-missing)

186 (100.0)

186 (100.0)

0.2585

 <100

63 (33.9)

71 (38.2)

 

 100–200

57 (30.6)

48 (25.8)

 

 201–400

35 (18.8)

45 (24.2)

 

 >400

31 (16.7)

22 (11.8)

 

ICS adherenceb

 n (% non-missing)

186 (100.0)

186 (100.0)

0.8806

 Mean (SD)

69.2 (55.2)

66.2 (53.3)

 

 Median (IQR)

54.8 (71.2)

56.1 (57.5)

 
  1. All values in the table are n (%) unless otherwise specified. High FeNO defined as ≥ 35 ppb; non-high FeNO < 35 ppb; high blood eosinophil count defined as ≥ 0.300 × 109 cells/L; non-high blood eosinophil count < 0.300 × 109 cells/L
  2. BMI body mass index, FeNO fractional exhaled nitric oxide, GERD gastroesophageal reflux disease, ICS inhaled corticosteroid, IHD ischaemic heart disease, IQR interquartile range, LABA long-acting β2-agonist, ppb parts per billion, SABA short-acting β2-agonist, SD standard deviation
  3. aActive denotes diagnosed in the year before FeNO reading or treated in the year before FeNO reading
  4. bMedication Possession Ratio was calculated by dividing the total of 1 day’s supply by the total number of days evaluated, multiplied by 100%. The evaluation period for all patients was 365 days in the study year
Back to article page

Clinical and Translational Allergy

ISSN: 2045-7022

Contact us